MediGene to buy UK's Avidex

Germany's MediGene has agreed to buy the UK's Avidex for $62.4 million in shares. MediGene gains the British biotech's pipeline of experimental therapies for cancer and autoimmune diseases. Advent Venture Partners owns a majority interest in Avidex, which is pushing RhuDex for rheumatoid arthritis into a pilot Phase IIa. The biotech was spun out of Oxford University in 1999. Other preclinical projects are built around Avidex's expertise in working with T cell receptors. The FDA recently extended its review of MediGene's ointment for genital warts.

- here's the release on the buyout

Suggested Articles

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.

The role gives one of the driving forces behind Bristol Myers Squibb’s $74 billion takeover of Celgene the chance to help build biotechs.

The appointment gives Sino-American biotech Brii the experience of a man who helped Gilead launch eight drugs in China in quick succession.